Pregled bibliografske jedinice broj: 1197391
The 2019 and 2021 International Workshops on Alport Syndrome
The 2019 and 2021 International Workshops on Alport Syndrome // European journal of human genetics, 30 (2022), 5; 507-516 doi:10.1038/s41431-022-01075-0 (međunarodna recenzija, pregledni rad, stručni)
CROSBI ID: 1197391 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The 2019 and 2021 International Workshops on Alport
Syndrome
Autori
Daga, Sergio ; Ding, Jie ; Deltas, Constantinos ; Savige, Judy ; Lipska-Ziętkiewicz, Beata S. ; Hoefele, Julia ; Flinter, Frances ; Gale, Daniel P. ; Aksenova, Marina ; Kai, Hirofumi ; Perin, Laura ; Barua, Moumita ; Torra, Roser ; Miner, Jeff H. ; Massella, Laura ; Galešić Ljubanović, Danica ; Lennon, Rachel ; Weinstock, Andrè B. ; Knebelmann, Bertrand ; Cerkauskaite, Agne ; Gear, Susie ; Gross, Oliver ; Turner, A. Neil ; Baldassarri, Margherita ; Pinto, Anna Maria ; Renieri, Alessandra
Izvornik
European journal of human genetics (1018-4813) 30
(2022), 5;
507-516
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni
Ključne riječi
Alport syndrome
(lport syndrome)
Sažetak
In 1927 Arthur Cecil Alport, a South African physician, described a British family with an inherited form of kidney disease that affected males more severely than females and was sometimes associated with hearing loss. In 1961, the eponymous name Alport syndrome was adopted. In the late twentieth century three genes responsible for the disease were discovered: COL4A3, COL4A4, and COL4A5 encoding for the α3, α4, α5 polypeptide chains of type IV collagen, respectively. These chains assemble to form heterotrimers of type IV collagen in the glomerular basement membrane. Scientists, clinicians, patient representatives and their families, and pharma companies attended the 2019 International Workshop on Alport Syndrome, held in Siena, Italy, from October 22 to 26, and the 2021 online Workshop from November 30 to December 4. The main topics included: disease re-naming, acknowledging the need to identify an appropriate term able to reflect considerable clinical variability ; a strategy for increasing the molecular diagnostic rate ; genotype- phenotype correlation from monogenic to digenic forms ; new therapeutics and new therapeutic approaches ; and gene therapy using gene editing. The exceptional collaborative climate that was established in the magical medieval setting of Siena continued in the online workshop of 2021. Conditions were established for collaborations between leading experts in the sector, including patients and drug companies, with the aim of identifying a cure for Alport syndrome.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
--IP-2014-09-2151 - Genotip-fenotip korelacija u Alportovom sindromu i nefropatiji tankih glomerularnih bazalnim membrana (GPofASandTBMN) (Galešić-Ljubanović, Danica) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava"
Profili:
Danica Galešić Ljubanović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE